Certara (CERT) Q1 2026 earnings review
A Messy Transition Quarter: Divestiture Clears the Deck, But Services Drag
Certara's Q1 2026 results confirm new CEO Jon Resnick's warning that this is a 'transition year.' Top-line growth practically stalled at 1% YoY ($106.9M), as the business story split into two extremes. Software bookings rebounded impressively (+20% YoY), but the Services division collapsed, with revenues down 4% and bookings plunging 14% due to severe go-to-market execution gaps. In a decisive move to simplify the business, Certara finally sold its Regulatory and Medical Writing division for an initial $85M. Excluding this divested unit, FY26 revenue guidance implies a stagnant 0% to 4% growth rate. The company is ripping off the band-aid, but the near-term financial picture is decidedly ugly, underscored by an $8.8M net loss.
🐂 Bull Case
After a concerning 6% drop in Q4, Software bookings surged 20% to $48.7M. This proves the core Model-Informed Drug Development (MIDD) platform remains sticky and resilient despite broader pharma spending hesitancy.
Selling the volatile Regulatory and Medical Writing business for $85M upfront removes a persistent distraction. Management expects the remaining company mix to be a highly attractive ~50/50 split between Software and Services.
🐻 Bear Case
Services revenue is reversing aggressively, dropping 4% YoY with bookings down 14%. Management openly cited 'execution and go-to-market challenges,' meaning this is an internal failure, not just a macro headwind.
Even after removing the divested business, organic growth guidance is a dismal 0% to 4%. The 'transition year' effectively means investors must wait until 2027 to see meaningful top-line expansion.
⚖️ Verdict: 🔴
Bearish. While the software bookings rebound and the medical writing divestiture are long-term positives, the severe execution failure in Services and the collapse in GAAP profitability overshadow the quarter. The 0-4% core growth guidance confirms a painful turnaround is underway.
Key Themes
Strategic Divestiture of Regulatory & Medical Writing
Certara completed the sale of its Regulatory and Medical Writing business to Veristat for $85M in cash, plus $15M in escrow and up to $35M in earn-outs. This is a massive strategic driver. It removes a lower-margin, inconsistent segment that generated ~$50M annually, allowing the new CEO to focus entirely on the high-margin, core biosimulation software and adjacent QSP services. It also injects immediate liquidity to fund the ongoing stock repurchase program or targeted tech acquisitions.
Software Bookings Accelerate Briskly
Accelerating. The biggest sigh of relief this quarter came from Software bookings, which jumped 20% YoY to $48.7M. This completely reverses the narrative from Q4, where a 6% decline in Tier 1 software renewals sparked fears of an AI-driven disintermediation. The bounce-back suggests that while sales cycles elongated last quarter, the fundamental demand for core platforms like Simcyp and Phoenix remains intact.
Accelerating the Enterprise AI Program
Management explicitly noted an 'accelerating enterprise-wide AI program' as a core pillar of the turnaround. Certara is heavily investing to ensure it is not disintermediated by internal pharma AI teams. By embedding AI into the Phoenix platform and scaling the newly launched CertaraIQ (which streamlines QSP modeling), the company aims to convert AI from a perceived competitive threat into a premium-priced module.
Services Execution is Reversing
Reversing. Services revenue contracted by 4% YoY ($57.2M), and bookings collapsed by 14% ($66.6M). CFO John Gallagher directly blamed 'execution and go-to-market challenges.' This contradicts the positive narrative from late 2025, where management claimed Services bookings (+17% in Q4) were a 'leading indicator' of market stabilization. Instead, internal execution has faltered, and a fix is not expected until the second half of the year.
Contingent Consideration Crushes GAAP Net Income
GAAP Net Income reversed sharply from +$4.7M a year ago to a loss of -$8.8M. The primary culprit was a sudden $7.4M spike in business acquisition contingent consideration expense (likely tied to the Chemaxon or Applied Biomath deals overperforming their earn-out targets). While this suggests acquired assets are doing well, the massive swing creates ugly headline optics and demonstrates poor visibility into earn-out liabilities.
Lagging Revenue Conversion
Decelerating. A specific data point that contradicts the strong Software bookings (+20%) is the actual Software revenue, which grew only 7% (down from 18% in the year-ago quarter). This indicates that while deals are being signed, revenue recognition is lagging, likely due to a higher mix of ratable/SaaS subscriptions versus upfront licenses, or delayed implementation timelines.
Biopharma Macro Hesitancy Lingers
The biopharma end-market remains tight. While the new CEO is taking responsibility for 'internal execution gaps,' the broader industry environment—characterized by lower biotech funding and large pharma budget scrutiny—continues to constrain deal velocity, particularly for large, discretionary Services projects.
Other KPIs
Decelerating. Adjusted EBITDA fell 9% YoY from $34.8M. Margin compressed to 29.6% (from 32.8% a year ago). Management is spending aggressively on executive recruiting, employee retention, and AI R&D, which is punishing bottom-line profitability during this transition phase.
Accelerating. Up 22% YoY ($12.7M increase). Beyond the $7.4M contingent consideration hit, Certara saw jumps in employee costs (+$2.8M), equipment/software (+$1.0M), and executive recruiting (+$0.9M). Cost control is moving in the wrong direction.
Decelerating. Total bookings fell 2% YoY. The 20% surge in software bookings was entirely erased by the 14% cratering in services bookings. Until both engines fire simultaneously, total company growth will remain grounded.
Guidance
Decelerating dramatically. This includes roughly $18M from the divested Regulatory/Medical Writing unit. Excluding the divestiture, management expects only 0% to 4% growth. This is a severe step down from the ~8% organic growth run-rate Certara historically commanded.
Stable. The company expects to maintain its margin profile despite the revenue reset. This implies management will execute targeted cost-cutting (or 'cost avoidance') in the back half of the year to offset the heavy Q1 OpEx burn.
Decelerating. The midpoint of $0.38 represents a noticeable contraction, reflecting lower operating leverage, a smaller top-line base post-divestiture, and ongoing R&D investments.
Key Questions
Services Turnaround Timeline
You cited 'go-to-market challenges' causing the 14% drop in Services bookings. Specifically, what broke in the sales motion, and why should investors believe these issues can be resolved as early as the second half of the year?
Use of Divestiture Proceeds
With the $85M upfront cash from the Veristat deal, how will you balance the existing $100M share repurchase authorization against the need for accelerated AI investments or M&A?
Contingent Consideration Volatility
The $7.4M contingent consideration hit wiped out GAAP net income. Which specific past acquisition triggered this, and should we expect further volatile earn-out liabilities through the rest of the transition year?
Software Revenue Recognition Lag
Software bookings grew 20%, but revenue only grew 7%. Is this divergence entirely due to ratable SaaS mix shifts, or are you experiencing delays in platform implementation and deployment at customer sites?